Jiangsu Vcare Unveils Phase I Clinical Trial Results of TRK Inhibitor VC004 at 2024 ASCO
Published Time:
2024-06-07 17:08
Source:
On June 2, 2024，Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) unveiled the Phase I clinical trial results of its self-developed next-generation TRK inhibitor, VC004, for the treatment of locally advanced/metastatic solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract ID: #3101
This study is a first-in-human, multicenter, single-arm, open-label Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT04614740). The Phase I portion is designed to evaluate the safety, efficacy, and pharmacokinetic (PK) profile of VC004 in patients with locally advanced/metastatic solid tumors.
Key Findings: During the Ib dose-expansion phase, 35 patients (median age: 57.0 years; 97% with ECOG score ≤1) treated with VC004 50 mg twice daily (recommended Phase II dose, RP2D) achieved unconfirmed and confirmed ORRs of 75.9%(95% CI: 56.5–89.7) and 69.0%(95% CI: 49.2–84.7), respectively, as assessed by RECIST v1.1 criteria.
In the subgroup of patients naive to TRK-TKI treatment, the unconfirmed and confirmed ORRs reached 80.8%(95% CI: 60.6–93.4) and 73.1%(95% CI: 52.2–88.4), respectively. Median DoR and PFS were not yet reached. Notably, 28.6% of TRK-TKI treatment-naive patients maintained responses for ≥12 months, and 75.8% achieved PFS ≥9 months. Among three patients who progressed after prior TRK-TKI therapy, two exhibited tumor shrinkage, including one partial response (PR; 39.6%). Of six patients with baseline brain metastases, two experienced intracranial lesion reductions of 61.8% and 25%, while non-target lesions achieved complete resolution in two others after four months of treatment.
Safety Profile, TRAEs were predominantly Grade 1–2, with no fatal TRAEs reported. Common TRAEs (≥20%) included dizziness, weight gain, hypertriglyceridemia, anemia, elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), hypercholesterolemia, and hyperuricemia. No new safety signals were observed compared to other TRK inhibitors.
VC004 demonstrated dose-proportional exposure across doses of 25–200 mg and favorable oral bioavailability.
VC004 exhibited safety comparable to first-generation TRK-TKIs and robust efficacy against NTRK fusion-positive tumors. Significant clinical benefits were observed not only in TRK-TKI treatment-naive patients but also in those with TRK-TKI resistant disease or baseline brain metastases.
Note: All data are preliminary and subject to confirmation in ongoing trials.
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn